The most recommended pharma & life sciences solution providers in 2021

The Most Recommended
Pharma and Life Sciences
Solution Providers in 2020
Featuring for the Cover Story is OnShore Technology
Group, a Chicago-based firm specializing in life sciences,
has developed lean valida on; an op mized valida on
process. It is designed to help eliminate waste and
inefficiencies tradi onally found in manual valida on
processes while streamlining and integra ng quality and
value to your company. This innova ve methodology will
ul mately conserve your resources enabling more cri cal
thinking and facilita ng more rigorous tes ng and
so ware assurance.
Started in the year 2004, Scube Scien fic is an ISO
9001:2015 cer fied renowned distributor of some of the
leading edge, easy to use and affordable scien fic
so ware tools pan India and also to the neighboring
The Pharma and Life Sciences industry has always
been driven by great innova on and research in the
drug development. In these challenging mes, it has
been pushed more than ever. Because the industry has
come up with promising and good quality drugs that have
had an immense impact in recovery rates, there have
been massive investments to back these innova ons.
This issue of The Business Fame of The Most
Recommended Pharma and Life Sciences Solu on
Providers in 2020 features some of the best companies
that have provided the world with their innova ve
solu ons and given a new turn to healthcare.
An bio c resistance is on the rise. The healthcare industry
is now in need of new an bio cs and therapies to treat
infec ous diseases and viruses. This is where pres gious
companies like Interna onal Health Management
Associates or IHMA enters. The company is working with
pharmaceu cal companies to develop new an bio cs and
therapies for infec ous diseases. They are also working
with diagnos c companies in order to test these new
an bio cs.
SAARC countries. Their services cater for assis ng the
research scien sts with tools that help them in their daily
scien fic ac vi es. Their marke ng and technical support
team work together with the clients to offer tailor-made
solu ons for their scien fic so ware needs.
Techsol Corpora on was founded in 2010 under the
leadership of Satya S. S Sagi, CEO with his vision for
offering value-based technology services and developing
innova ve so ware solu ons for pharma. With over 20
years of life sciences industry experience, the humble
beginnings of Techsol were started by him on a small
penthouse overseeing Hi-Tec city in Hyderabad, India.
Today with our headquarters in Princeton, NJ, we are
recognized as a valuable tech partner for several global
clients with an expanded team of 140+ subject ma er
experts.
™

ISO 9001:2015 Certied Media Firm
™

Scube Scientific Software Solutions Pvt. Ltd.
Innovative and Affordable Scientific Software Solutions
16
International Health Management Associates
Redefining the Drug Discovery Process with Unique
Solutions
20
Techsol
Developing Innovative Software Solutions
and Technology Expertise for Pharma
24
BEST OF PHARMA AND LIFE SCIENCE
A 16 Year Legacy Empowering Life Science
Businesses with Automation
The pharmaceutical
sector finally gets
the recognition
it deserved
32
ARTICLE
COVER STORY
TECHNOLOGY GROUP 08
ONSHORE
What is Coronavirus?
32

™
Scube Scientic
Software Solutions
Pvt. Ltd.
Innovative and Affordable
Scientic Software Solutions
Debasish Bhattacharya
Director
16 | MARCH 2021

17 | MARCH 2021
™
By carefully examining the situation, Debasish
Bhattacharya thought of entering into this vertical of
software development. Scube Scientific is a company that
provides affordable and innovative scientific software
solutions.
Scube Scientific is one of the most reputed and highly
practised companies that promises an unmatched expertise
in the fields of Computational Chemistry, Biology,
Mathematical Modeling, Statistical Analysis, Data Mining
and Market Research. With their outstanding and
innovative services, the company has collaborated with
some of the most renowned companies of the world like
Gaussian Inc., Wolfram Research Inc., and PerkinElmer
Informatics, to name a few.
Started in the year 2004, Scube Scientific is an ISO
9001:2015 certified renowned distributor of some of the
leading edge, easy to use and affordable scientific software
tools pan India and also to the neighbouring SAARC
countries. Their services cater for assisting the research
scientists with tools that help them in their daily scientific
activities.
lobalization has brought the world closer, and the
Guse of IT, the development in many sectors has
made the operations easy and effective. The
scientific advances depend on the ideas, conceptual leaps
and the paradigm shifts. The fast evolving nature of these
industries has urged the necessity of software solutions in
different arenas of the industry.
The Company-
Their marketing and technical-support team work together
with the clients to offer tailor-made solutions for their
scientific software needs. Their operational excellence is
derived from the responsiveness and over a decade of
experience working on a wide range of software,
platforms and technologies.
Initially, the company's major challenge came from the
unawareness of people about the utility of computer
software in scientific research. So it took them quite a long
time to convince professors and scientists of the utility and
functionality of the software.
The issue was simple. They did not feel the need to push
their sales, but what they basically did was talk to the
actual user and try and understand their need and align the
product based on that need.
The Initial Challenges and How Scube Triumphed-
“We believe that some of the company's core factors have
really contributed to a great deal in leading our
organization on the path to success.”
Scube Scientific offers a wide range of products and
services to its clientele. The innovation in their services
has helped research scientists carry out their tasks
effectively.
These include-
Ÿ Dedicated manpower
Ÿ Trying to offer proper service to our clients
Ÿ As a solution provider approach
Ÿ Right product offering
Ÿ Very adaptive in approach
The Products and Services-
What the Clients Think-
The company has pursued a long-term vision to provide
integrated portfolio of software and services to scientific
research institutes, academia, industry and the
Government. Its dedication and expertise has earned an
array of distinguished clients such as DRDO, CSIR Labs,
and every major IIT and University. In addition to that, its
experienced team of Application Specialists brings
together knowledge and domain expertise to provide you
streamlined solutions in the fields of Computational
Chemistry, Computational Biology, Mathematical
Modeling, Statistical Analysis, Data Mining and Market
Research.
“Wolfram trainers delivered lectures on Wolfram
Mathematica during the “Short term course on software
tools for scientific research: Mathematica and LateX”
organised by department of Mathematics and Mechanical
Engineering, MNIT Jaipur. We appreciate Scube effort in
the successful completion of the event.” - Dr. Rashmi Jain,
Department of Mathematics and Mechanical Engineering,
MNIT Jaipur.
“I thank Scube for its very good follow up to get
SCIGRESS and ADMEWORKS ModelBuilder installed. I
am happy with your reciprocation towards your customers.
I assure to improve the business with you by procuring
softwares from you.” - Dr. Kajal Chakraborty, Central
Marine Fisheries Research Institute.
“We appreciate the service provided by Scube Scientific
software solutions during the complete process of
Gaussian TCP Linda purchase and implementation. Scube
Team has good knowledge about Gaussian &GaussView
packages as well as excellent skills in Linux platform. We
wish them the best for their future.” - Prof. Arup Banerjee,
Theory and simulation Lab, Raja Ramanna Centre for
Advanced Technology Indore.

18 | MARCH 2021
™
Know the Leader
Debasish Bhattacharya Leading the Way
Mr. Debasish Bhattacharya, who has over 20 years of experience in IT sales,
started this business in the year 2004. During that time, idea about IT only enclosed
office automation but no IT initiative on scientific research. Hence, Mr. Debasish
thought of creating a business which can help research scientists with appropriate
tools that will help them in their daily scientific research activities.

INTERNATIONAL
HEALTH MANAGEMENT
ASSOCIATES
Redening the Drug Discovery Process with
Unique Solutions
John Jackson
CEO
™
20 | MARCH 2021

It's a charismatic century where the world is changing
its way by adopting and adapting to the technological
disruptions. Numerous scientific developments and
innovations take place throughout industries including
pharmaceutical and healthcare industries every single day
improving human health and forwarding life-expectancy
one step further. However, the cost of drug-development or
discovery processes continues to rise and the chances of
success continue to plummet. According to McKinsey,
every year, the top 20 pharmaceutical companies spend
approximately $60 billion on the research and
development of drug discovery.
The drug discovery process consists of steps of
identification of candidates, synthesis, characterization,
screening, and assays for therapeutic efficacy.
Antibiotic resistance is on the rise. The healthcare industry
is now in need of new antibiotics and therapies to treat
infectious diseases and viruses. This is where prestigious
companies like International Health Management
Associates or IHMA enter. The company is working with
pharmaceutical companies to develop new antibiotics and
therapies for infectious diseases. They are also working
with diagnostic companies in order to test these new
antibiotics.
The Leading Light of IHMA
Jack Johnson, the CEO of IHMA, has years of experience
in the pharmaceutical industry such as Pfizer, Beecham
Laboratories and G.D. Searle. He founded the company in
1992 with an aim to help the pharmaceutical companies to
meet the challenges prevailing in the drug development
industry. During the 18-years of experience in the
pharmaceutical industry, he launched products named
cefoperazone, amoxicillin/clavulanic acid,
ticarcillin/clavulanic acid, mupirocin and lomefloxacin
respectively.
This is the efforts of Jackson, IHMA has become one of
the world's leading providers of antimicrobial drug
development support. The company offers complete
collaboration and flexibility with all of their clients around
the world ensuring ongoing development success.
As the leading global microbiology service provider to the
biopharmaceutical industry, IHMA's mission is to utilize
their widespread laboratory and industry expertise to
support efficient and effective anti-infective product
development.
Outstanding Products and Services
Full service microbiology and molecular laboratories are
the most distinguishing services of IHMA. It is a leading
benefactor of antimicrobial drug development studies that
offers an all-inclusive domain proficiency in all stages of
antimicrobial drug development. The phases of
antimicrobial drug development include: drug discovery,
clinical development, regulatory approval and
commercialization. With branches in the USA, Europe,
India, and China, IHMA collaborates with companies
around the world in the pharmaceutical, biotechnology and
diagnostic device industry.
The clients of the company include those organizations
who need:
1.Pre-clinical studies including in vitro and
pharmacodynamic studies
Ÿ MIC Profile
Ÿ Bacterial
Ÿ Bacteriophage
Ÿ Molecular Characterization of AMR
The Phases and Expertise of IHMA in Antimicrobial Drug
Development
Ÿ Fungal
Ÿ WGS Diagnostics
Ÿ Time Kill
Ÿ Diagnostic Devices
3.Antimicrobial resistance (AMR) surveillance
Ÿ Therapeutics
2.Global support of all phases of clinical trials
Ÿ Support with New Therapeutic Approaches
Ÿ Resistance Development
As mentioned earlier, IHMA supports all phases of
antimicrobial drug development, from discovery to
commercialization.
IHMA reserves incomparable expertise in the spheres of
microbiology, pharmaceutical, medical, and diagnostic.
This highly elevated skill set ensures effortless success for
the phases of drug development, clinical trial support,
regulatory approval and commercialization.
21 | MARCH 2021
™

22 | MARCH 2021
™
The process of discovering new anti-infective entirely
depends upon the well-timed generation of relevant and
informative data. The full suite of technical competences,
resources, and domain expertise of IHMA employees are
enough to support the discovery needs of the clients in a
collaborative and flexible manner.
The proficiencies in the drug discovery include:
Ÿ Bacterial Repository
Clinical Development
Ÿ Central Laboratory Microbiology Services
Ÿ Clinical Scientific Expertise
Drug Discovery:
Ÿ Specialized Microbiology Laboratory Services
“We are always evaluating cutting-edge technologies and
novel study designs to support changing infectious disease
field”
Among the many challenges in the way of designing a
clinical product, economic constraints, uncertain
regulatory landscapes, and the continuous evolution of
unique strategies for the prevention and treatment of
infectious diseases are significant.
The technical competencies in clinical development
include:
Regulatory Submission
Ÿ Central Laboratory Microbiology Services
Ÿ Antimicrobial Resistance Surveillance
A successful regulatory outcome depends on many factors
including scientifically and clinically sound data, presented
in a concise and coherent manner. From the microbiology
perspective, the expert team of IMHA ensures that these
goals are met with their proficiency in the domain.
Commercialization
Expertise in Regulatory submission include:
Areas of Expertise
The timing of educating the global clinical and scientific
community about the new product's attributes, and the
ability of local clinical microbiology laboratories to test
the product against the organisms they encounter in their
clinical settings are considered as the main attributes for a
successful commercialization. IHMA offers a number of
solutions uniquely suited to be used in a collaborative and
successful manner to help develop a successful plan for
commercialization.
Ÿ Manufacturers Interface and Performance Program
(MIPP)
Ÿ Antimicrobial Voluntary Evaluation Program (AVEP)
Ÿ Antimicrobial Resistance Surveillance
Ÿ Surveillance Data Link Network (SDLN)
Contribution of IHMA to the Development of the
Industry
IHMA is a premier provider of antimicrobial drug
development studies. With laboratories in both the US and
Europe, the company partners with clients around the
world in the biotechnology, pharmaceutical, and diagnostic
fields. IHMA is a leading, independent laboratory
specializing in surveillance studies and clinical trials,
creating key milestones along–the continuum from drug
development to commercialization. The company also
utilizes state-of-the-art technology, which enables the team
in first-class testing and data as well as sound economic
frameworks. The services offered by IHMA are
customizable to best align with the unique testing needs of
the clients. This ensures successful drug development,
commercialization, and post-marketing pathways.
While asked about what the future holds for the company,
John Jackson, the CEO, asserted, “We are always
evaluating new technologies and new study designs to
support the changing infectious disease therapy field. For
example, the use of technology such as MALDI-TOF and
whole genome sequencing is shifting from experimental
technology to standard laboratory procedures.”

TECHSOL
Developing Innovative
Software Solutions and
Technology Expertise for
Pharma
Satya S S Sagi
founder and CEO
24 | MARCH 2021
™

25 | MARCH 2021
™
In the Medical Affairs domain, we began developing
“MedInquirer” about 4 years ago and this was our first
cloud solution just for medical communications. Today, we
Techsol Corporation was founded in 2010 under the
leadership of Satya S S Sagi, CEO with his vision for
offering value-based technology services and developing
innovative software solutions for pharma. With over 20
years of life sciences industry experience, the humble
beginnings of Techsol was started by him in a small
penthouse overseeing Hi-Tec city in Hyderabad, India.
Today with our headquarters in Princeton, NJ, we are
recognized as a valuable tech partner for several global
clients with an expanded team of 140+ subject matter
experts.
Introduction and Background of the company
We provide business-value to our clients by delivering
high-quality configurable solutions & specialized services
with the focus on quality and regulatory compliance. Our
core domain expertise was developed using our committed
domain experts through constant industry interactions, and
by adopting industry best practices. For eg: All validation
services we provide are in alignment to the GAMP5 risk-
based validation framework. Our Service Desk operations
are run by using the principles of ITIL and we deliver
projects using the PmBOK methodology.
We currently focus on providing technology and
technology enabled data services to address some of the
specific challenges of Pharma in the R&D, Medical Affairs
and Commercial processes. In the Clinical Development
and Pharmacovigilance, we offer system integrations
services and Managed cloud services (Accel Solutions) in
partnership with Oracle Health Sciences. We are also
actively developing a PVSentinel platform that addresses
some of the operational challenges of Pharmacovigilance
by utilizing AI/ Automation and digital approaches.
With over 10+ years of industry experience, we have learnt
that keeping up a commitment and winning the trust of
clients comes only with diligence, integrity, transparency,
and continuous pursuit of excellence. In short these have
been our ingredients to develop a sustainable innovation
mindset regardless of shortcomings. Above all, we have
developed the virtue of being agile to adapt, evolve and
align ourselves constantly with our client's business goals.
Keeping up to speed with rapid advancements in
technology requires a considerable amount of dedication to
reduce talent development time. Understanding the
challenge and offering the right solution for clients with
changing tech requirements is a key specialty for us
because we have learned to thrive with agility.
Our commitment to introduce high-end technology
through SciMax for Medical Affairs will be a game
changer for Pharma & Service providers. We will be the
first company to provide such a comprehensive
collaborative platform for multi-functional stakeholders.
As we look more closely, we know for a fact that this
adaptive change requires synergy with other business
systems. Hence, we have dedicated ourselves to building
configurable technology solutions which can easily support
cross-platform integrations.
Joe Pierce, CEO, SciMax Global says, “I've been in the
industry for nearly 25 years and Techsol's SciMax is
simply the best Medical Affairs solution available. We
are extremely excited to continue to enhance, develop,
implement, and support for end to end management of
Medical Affairs
have broadened our innovation landscape by launching
SciMax Global (www.scimaxglobal.com) which is a
patient-centric Outcomes & Evidence driven global
medical affairs platform.
Ÿ Build & deliver configurable, process-oriented digital
platforms for pharma
With all the market entry barriers, timing is an essential
component of innovation success. Its primarily for that
reason, we have established synergetic relationships with
our clients and partners to derive value from their
knowledge and to offer our technology expertise. Another
important success factor that we were able to leverage
successfully is our tactical capability to reuse technical and
knowledge assets to solve problems more effectively.
Ÿ Provide lean and integrated cloud solutions
Business Challenges associated with offering
Technology driven services to Pharma
Ÿ Offer actionable intelligence with advanced data
analytics
With our pharma industry domain expertise & strong
technology experience, we have proven capabilities to:

26 | MARCH 2021
™
Ÿ Transform business processes with incremental
innovation
“Our vision is to become a pioneer in providing value-
driven, high quality, process-oriented technology services
and simplified business solutions for the pharmaceutical
industry,” says Satya S S Sagi, founder and CEO of
Techsol
Working with Strategic customers
We have been providing unparalleled technical and
functional consulting guidance across the clinical
development, drug safety and medical affairs verticals with
strategic business partnerships. We had the opportunity of
implementing and rolling out SciMax Platform for both a
multi-national rare disease pharma and a global Med Info
Contact Center. Both our clients were looking out for a
purpose-built configurable solution that can be tailored and
scaled up as their business needs grow. The multi-channel
intake, cross-platform integrations, robust case
management workflows, built-in reporting & analytics has
given them considerable advantage to automate manual
tasks and have one single comprehensive solution for all
their medical communication needs.
In return, their knowledge capital has been extremely
valuable in further strengthening the product's competence.
With two major version releases, today we can claim that
SciMax is one of the most advanced cloud solutions in the
industry. And we haven't stopped here because we are
already working on the next big wave in infusing artificial
intelligence capabilities.
New Capabilities
We are actively working towards announcing the launch of
multiple new products and services during this year. Our
appetite for innovation has increased with our domain
knowledge. Major announcement is the launch of
“PVSentinel” cloud solution for pharmacovigilance
operations oversight and compliance governance.
PVSentinel is a process orchestration and compliance
governance solution to streamline, track and report the
outcomes of PV operations and cross-functional activities
managed by different vendors, partners and affiliates.
We are also working on expanding our service lines to
address tech and tech enabled data service capabilities
across compliance and quality processes of R&D, Medical
and Commercial. We are working towards launching new
tech verticals such as Quality, Manufacturing/ Supply,
Work Culture and Team
Our talent pool is constantly nourished with continuous
knowledge capital, autonomous work ownership, festival
get-togethers, social cause shouldering, individual and
team empowerment. All these elements positively
influence our team to bridge with clients, understand their
business goals and work towards common success.
First and foremost, Techsol's work culture is fabricated
with each team members commitment towards positive
outcomes in anything we do. The close-knit collaboration
amongst our team members has been visibly recognized by
all our clients and that has encouraged our enthusiasm to
provide high-quality services all these years. As part of
our corporate responsibility, we have established an
amicable work environment with open-door policy, talent
recognition, continuous learning support and celebrating
our success together.
Patient Engagement etc. and new horizontal services such
as tech enabled Pharmacovigilance data services.
“Our vision is to
become a pioneer in
providing value-
driven, high quality,
process-oriented
technology services
and simplified
business solutions
for the
pharmaceutical
industry,”

27 | MARCH 2021
™
For anyone who has dreamed to take the path of Pharma
tech entrepreneurship, having the right sense of timing is
critical to launch an innovation in a heavily crowded tech
market. For new service providers, having the right
partnership model is crucial to go against market barriers.
Understanding current market trends, innovation
landscape, staying updated on regional regulations,
observing the pace of technology adoption and gaining
competitive intelligence is of paramount importance to win
against the odds. The challenge for any new tech
innovation in this arena will continue to revolve around
quality, compliance and risk. Another key element is to
develop and offer solutions that will continue to scale and
grow for your clients over the years.
We provide growth enabling a competitive environment,
invest our resources to foster and develop their growth as
leaders. Our leadership team that includes engineers, client
specialists, sales gurus, scientists, and entrepreneurs,
leverage their collective wisdom and capabilities
cohesively to create and deliver organization wide focus on
client delight. Techsol' dedicated team works across its two
global offices in Princeton (NJ), Hyderabad (India) and
Seoul (South Korea) to support our global clientele. Our
consistent success in delivering client delight is due to
seamless harmony and teamwork between our staff,
leadership and board.
With the advent of Artificial Intelligence use in many other
industries, pharma is preparing its aptitude to gradually
adopt it for next generation healthcare. Like any new
technology, there is also a great amount of scepticism to
Entrepreneur Challenges in the space
The learning curve for mastering tech solutions is pretty
steep especially in the pharma industry because of
stakeholder variances, cross-functional processes,
compliance obligations and the vastness of the tech
ecosystem. Today company mergers and acquisitions have
increased in multiple folds, therefore there is very little
margin to win or lose an opportunity.
The executive leadership from behind the scenes have
been instrumental to ensure that all team members get the
best of every client interaction as it an opportunity for
them to contribute with their competence and increase the
value of the entire business relationship.
AI and Next Generation Tech Adoption by Pharma
Ÿ Matured, audit ready Quality Management System with
relevant certifications, standards, data privacy &
protection
believe and accept what AI is perceived to do as to what it
really can do.
Ÿ Most preferred strategic partner for Oracle health
sciences, world's largest pharma focused enterprise
software company. Very strong techno functional
system integration skills on world's leading drug safety
database – Argus Safety
Ÿ More than 50 Satisfied and Referenceable pharma
customer base across solution areas
Ÿ Established, regulatory compliant GxP cloud designed
for emerging pharma companies
The fruitful outcomes of AI pilot projects are claiming that
it can be a boon for winding down redundant costly
processes. Perhaps, it's true that continuously trained
intelligent algorithms can prove their benefit without
doubt. But is the industry willing to put AI to work
especially for making critical healthcare decisions or for
discovering new paths of disease treatment? Perhaps we
will get there soon enough to know it for real.
Key strengths of Techsol:
Ÿ Specialized, innovative, software solutions and services
company serving Global Pharmaceutical, Life sciences,
and Healthcare companies in three verticals – Medical
Affairs, Drug Safety and Clinical Development
Ÿ Strong presence and leadership position in the fast
growing Asia Pacific pharma market. Fast growing
company in North America market. New entrant in EU
and middle east
Ÿ Strong promoters and leadership team with committed
involvement in company growth over the past 9 years

FINALLY GETS THE
RECOGNITION
IT DESERVED
PHARMACEUTICAL
SECTOR
THE
30 | MARCH 2021
™

31 | MARCH 2021
™
A
lthough the ongoing
COVID-19 pandemic has
signiﬁcantly impacted
several sectors across the
world, it comes as a silver lining
for the pandemic
pharmaceutical sector. In the
last few months, Pharma
companies across the world
have had a good run across the
world. It has managed to
become the most preferred
stock amongst various portfolio
managers, as stock markets
recording all-time high across
almost all nations. This growth
may seem overhyped to a lot of
people due to the covid
scenario, but experts beg to
differ. According to them,
pharma is ﬁnally representing
its genuine valuation in the
market.
However, here comes a
question, how can an essential
sector like pharma be
undervalued for such a long
time? Well, a short answer here
would be stringent regulatory
norms. To simply put, it was
challenging for pharmaceutical
companies to cope up with the
regulatory standards. For the
past decade, these
pharmaceuticals have found
Optimism in pharma is at an all-
time high. We can see the
evidence of this in global stock
markets. However, experts are
still uncertain about their long-
term trajectory. A crucial
element that concerns the
future of this sector is the
FDA's stance after the
lockdown ends. If regulations
go back to remain stringent for
companies then the businesses
are surely expected to slowly
evaporate as earlier.
But with the pandemic in full
throttle, the businesses seem to
have returned in huge lots as
regulators decide to levy
numerous rules. This has
encouraged U.S enterprises to
partner with manufacturers
worldwide to tap major market
share during these challenging
times.
themselves under heavy
scrutiny from agencies like the
U.S FDA, with some even
receiving frequent warning
letters every now and then.

WHAT IS
CORONAVIRUS?
34 | MARCH 2021
™

35 | MARCH 2021
™
T
he Coronavirus is a group
of all the infections that
can cause numerous
scopes of illnesses in people.
Sicknesses like the basic cold
and progressively extreme
structures like SARS and MERS
are dangerous.
HIGHLIGHTS
Ÿ Three suspected cases of the
coronavirus were reported in
the Delhi today
Ÿ India is not fully prepared to
cope with the mysterious
coronavirus.
The WHO (World Health
Organization) in its most recent
report on Coronavirus
circumstance said that there
was a high danger of the
infection in all over China and
high at the territorial and
worldwide levels.
Ÿ Death toll crosses almost 130
in China, India steps ups its
preparations to tackle the
crisis
Coronavirus began in China's
Wuhan region, the fatal
Coronavirus has now spread to
over twelve major nations
including the United States,
This infection has spread to
each edge of the world with
right around 19 nations,
including India's neighbors Sri
Lanka and Nepal. At last, the
infection can possibly spread
quickly to different nations due
to its propensity to spread
human-to-human transmission,
as per the World Health
Organization.
The patients who had returned
once again from China as of
late, were admitted to the RML
Hospital (Dr Ram Manohar
Lohia) in New Delhi with
comparable respiratory
manifestations to those of the
dangerous ailment at present
grasping the world.
Japan, India and South Korea.
The majority of the signiﬁcant
International air terminals in
India are on high caution and
are screening all the travelers
originating from China and
different nations. Numerous
individuals are held under
perception for this associated
case with coronavirus in various
urban communities of India, for
example, Hyderabad, Mumbai
and New Delhi.

TBF team is extremely approachable and eﬃcient. I am
very impressed by their professional attitude and the
readiness to improve.
Gautam Chaturvedi | Founder & MD | Pine Tree Pictures
“Thank you The Business Fame Magazine for
featuring us in your COVID-19 edition. We wish
you all the very best in your endeavors ahead”
Dr. Sanjay Arora | Managing Director
Suburban Diagnostics India Pvt. Ltd.
I found The Business Fame Magazine team very
professional. Am quite happy to deal with them,
the write up editing and quality is very good.
Koheli Puri | Founder & MD | Studio XP

The most recommended pharma & life sciences solution providers in 2021

The most recommended pharma & life sciences solution providers in 2021

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to The most recommended pharma & life sciences solution providers in 2021

Similar to The most recommended pharma & life sciences solution providers in 2021 (20)

Recently uploaded

Recently uploaded (20)